Browse News
Filter News
Found 1,128 articles
-
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
4/18/2024
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
-
Evotec welcomes Aurélie Dalbiez as Chief People Officer
4/17/2024
Evotec SE announced the appointment of Aurélie Dalbiez as the Company's new Chief People Officer, effective 15 June 2024.
-
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
4/17/2024
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.
-
Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024
4/10/2024
Blacksmith Medicines, Inc. (Blacksmith) today announced preclinical data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 at the San Diego Convention Center, San Diego CA.
-
Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting
4/8/2024
Immunitas Therapeutics ("Immunitas") today presented preclinical data supporting the combination potential of IMT-009 with anti-PD1 immunotherapy at the American Association for Cancer Research Annual Meeting (AACR 2024) in San Diego, California.
-
Blacksmith Medicines to Present at the 23rd Annual Needham Healthcare Conference
4/3/2024
Blacksmith Medicines, Inc. today announced that it will present a company overview and participate in 1x1 meetings at the 23rd Annual Needham Healthcare Conference on Thursday, April 11, 2024 at 11:00 am ET.
-
AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING
3/28/2024
Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor.
-
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
3/21/2024
Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to announce that it has entered into an exclusive licensing agreement with Sovargen Co., Ltd, a biotechnology company specializing in central nervous system (CNS) diseases, to develop, manufacture and commercialise paxalisib as a potential treatment of intractable epilepsy in focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC) disease.
-
Blacksmith Medicines to Present at the Gordon Research Conference on New Antibacterial Discovery and Development
3/19/2024
Blacksmith Medicines, Inc. announced today that it will present a talk and poster highlighting its novel chemistry technology platform for metalloenzyme inhibitors of LpxC being held March 17-22, 2024, in Ventura, CA.
-
The German biotech Thursday said the proceeds from the Series B2 round will support clinical evaluation of its lead solid tumor antibody-drug conjugate candidates and expansion into the U.S.
-
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
3/14/2024
Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.
-
Kazia announces presentation of new data at AACR Annual Meeting
3/13/2024
Kazia Therapeutics Limited is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024.
-
Blacksmith Medicines Announces Upcoming Presentation at AACR Annual Meeting 2024
3/6/2024
Blacksmith Medicines, Inc. announced the company will present data on its oncology program targeting flap endonuclease 1, a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 at the San Diego Convention Center, San Diego CA.
-
Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting
3/5/2024
Immunitas Therapeutics announced it will present preclinical data supporting the combination potential of IMT-009, its first-in-class anti-CD161 antibody under clinical evaluation for use in solid tumor and hematologic malignancies, with anti-PD1 immunotherapy at the American Association for Cancer Research Annual Meeting, held April 5-10 in San Diego, California.
-
Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)
2/27/2024
Domain Therapeutics today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO).
-
Blacksmith Medicines Announces $3.3M in Funding from NIAID to Support Clinical Trial Manufacturing of Novel Antibiotic
2/21/2024
Blacksmith Medicines, Inc. announced the release of $3.3M from its contract with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Department of Health and Human Services, to conduct IND-enabling and Phase 1 studies of FG-2101, its novel non-hydroxamate LpxC inhibitor, using both intravenous and oral administration for the treatment of urinary tract infections caused by multidrug-resistant Gram-negative bacteria.
-
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
2/21/2024
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial.
-
5 Companies Hiring Scientists Now
2/15/2024
If you’re a researcher looking for your next challenge, check out these companies with current openings on BioSpace. -
Blacksmith Medicines and Zoetis Announce Research Collaboration for Novel Animal Health Antibiotics
2/14/2024
Blacksmith Medicines, Inc. and Zoetis announced a collaboration to discover and develop novel antibiotics for animal health.
-
Evotec SE: Invitation to Conference Call - Jan 22, 2024
1/22/2024
Evotec SE is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.